NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-22-204 from the NIH Guide for Grants and Contracts
Notice NOT-AI-22-073 from the NIH Guide for Grants and Contracts
Notice NOT-DE-22-016 from the NIH Guide for Grants and Contracts
Notice NOT-AG-22-029 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this FOA are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and potential new targets for therapeutic development.
Notice NOT-DA-22-071 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-045 from the NIH Guide for Grants and Contracts
Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-22-235 from the NIH Guide for Grants and Contracts. This initiative is designed to promote discovery of cellular and molecular mechanisms that underlie brain blood vessels responses to passive anti-beta-amyloid immunotherapy that result in amyloid-related imaging abnormalities (ARIA). The goal is to establish an understanding of molecular mechanisms that can be targeted to protect the blood brain barrier (BBB), and thus the brain blood vessels, during therapeutic interventions that target beta-amyloid.
Notice NOT-DC-22-010 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-295 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-234 from the NIH Guide for Grants and Contracts. The MetNet is a collection of Research Centers that support using systems level approaches to understand the non-linear, dynamic and emergent processes in metastasis. Considering chronological progression and biological scales, the MetNet seeks to collectively derive a more comprehensive and cohesive picture of metastasis as a whole body, systems-level problem.
Funding Opportunity PAR-22-227 from the NIH Guide for Grants and Contracts. The purpose of the NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence.
Funding Opportunity PAR-22-226 from the NIH Guide for Grants and Contracts. The purpose of the Research and Entrepreneurial Development Immersion (REDI): NIA Entrepreneurship Enhancement Award (R25) is to promote the development of entrepreneurial training programs that are designed to broaden the skillset of graduate students and postdocs, as well as early career master's, Ph.D., and Dr.P.H. scientists, in fields relevant to the mission of NIA, including aging and Alzheimer's disease (AD) research. The goal of this program is to prepare trainees for a wide range of career paths, including those that are outside the normal research environment.
Funding Opportunity PAR-23-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere. Projects must be consistent the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been most recently been described in NOT-OD-20-018.
Funding Opportunity PAR-22-224 from the NIH Guide for Grants and Contracts. This FOA will support creative educational activities that focus primarily on research skills development. . Although activities focused primarily on mentoring activities or professional skills development are not within the scope of this funding announcement, the informal mentoring activities and professional skills development that are usually associated with courses for research skills development are permitted.
Notice NOT-DK-22-026 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-028 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.
Notice NOT-CA-22-121 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-030 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for a Coordinating Center for the Cancer Adoptive Cellular Therapy (Can-ACT) network. The Can-ACT network of research sites will advance collaborative and novel approaches for adoptive cell therapy for solid tumors, with an emphasis on the transition from preclinical testing and translational studies to early phase clinical trials. The Coordinating Center will provide leadership to the Can-ACT network, facilitate data sharing and collaboration, and coordinate clinical trial activities between research sites and the NCI.
Funding Opportunity RFA-CA-22-029 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.